In a trial involving patients with COPD and type 2 inflammation shown by elevated blood eosinophil counts, treatment with dupilumab reduced disease exacerbation and improved lung function.
In a trial involving patients with COPD and type 2 inflammation shown by elevated blood eosinophil counts, treatment with dupilumab reduced disease exacerbation and improved lung function. The New England Journal of Medicine: Search Results in Allergy/Immunology
